ESHO 1-85:热疗作为放疗辅助手段治疗局部晚期乳腺癌——欧洲热肿瘤学会随机多中心研究
该随机多中心试验纳入151例患者共155个局部晚期乳腺癌肿瘤,比较单纯放疗(65-70 Gy)与放疗联合每周热疗(目标43°C持续60分钟)的疗效。可评估146个肿瘤中,联合热疗组5年局部失败率50% vs 单纯放疗组68%(p=0.04),热疗为唯一显著预后因素(HR 0.61)。联合热疗组无病生存率36% vs 19%(p=0.021)。
要点
- 联合热疗组5年局部失败率50% vs 单纯放疗组68%(p=0.04)。
- 联合热疗组无病生存率36% vs 单纯放疗组19%(p=0.021)。
核心结论
- 在局部晚期乳腺癌放疗中加入每周热疗可显著提高5年肿瘤控制率并使更多患者无癌生存。
- 结果证实了热肿瘤学的潜在临床获益。
研究设计与样本
- 欧洲热肿瘤学会发起的多中心随机试验(ESHO 1-85),1987年2月至1993年11月纳入151例患者共155个肿瘤。
- 肿瘤按机构和大小(T2-3/T4)分层,随机分配至单纯放疗(2 Gy/次,5次/周,总剂量65-70 Gy含推量)或相同放疗后每周一次热疗(目标43°C持续60分钟)。
- 主要终点为治疗区域持续完全缓解(局部控制)。
主要发现
- 可评估146个肿瘤(142例患者),中位观察时间19个月(范围1-134个月);单纯放疗组70个肿瘤,联合热疗组76个肿瘤。
- T4期92个肿瘤,T2-3期54个肿瘤;除4例患者外,所有患者均完成计划放疗。
- 热疗耐受性尚可,但15%的治疗出现中度至重度疼痛和不适;84%的热疗患者至少一次热疗达到目标温度,但温度变化很大。
- 加入热疗未显著增加急性或晚期放射反应。
- 总体5年实际局部失败率为57%;单因素分析显示热疗(单纯放疗组68% vs 联合热疗组50%,p=0.04)和T分期(T4期75% vs T2-3期36%,p<0.01)有显著影响。
关键数值与推荐
- 放疗方案:2 Gy/次,5次/周,总剂量65-70 Gy(含推量)。
- 热疗方案:每周一次,目标43°C持续60分钟。
- 5年局部失败率:单纯放疗组68% vs 联合热疗组50%(p=0.04)。
- T分期局部失败率:T4期75% vs T2-3期36%(p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ESHO protocol 1-85 is a multicenter randomized trial initiated by the European Society for Hyperthermic Oncology with the aim to investigate the value of hyperthermia (HT) as an adjuvant to radiotherapy (RT) in treatment of locally advanced breast carcinoma. The trial is one of the largest studies of hyperthermia in radiotherapy but has not been previously published. PATIENTS AND METHODS: Between February 1987 and November 1993, 155 tumors in 151 patients were included. Tumors were stratified according to institution and size (T2-3/T4) and randomly assigned to receive radiotherapy alone (2 Gy/fx, 5 fx/wk) to a total dose of 65-70 Gy, incl. boost, or the same radiotherapy followed once weekly by hyperthermia (aimed for 43 °C for 60 min). Radiation was given with high voltage photons or electrons. The primary endpoint was persistent complete response (local control) in the treated area. RESULTS: A total of 146 tumors in 142 patients were evaluable, with a median observation time of 19 (range 1-134) months. Seventy tumors were randomized to RT alone and 76 to RT + HT. Size was T4 in 92, and T2-3 in 54 tumors, respectively. The compliance to RT was good with all but 4 patients fulfilling the planned RT treatment. The tolerance to HT was fair, but associated with moderate to severe pain and discomfort in 15 % of the treatments. In 84 % of the heated patients a least one heat treatment achieved the target temperature, but the temperature variation was large. Addition of heat did not significantly increase the acute nor late radiation reactions. Overall, the 5-year actuarial local failure rate was 57 %. Univariate analysis showed a significant influence of hyperthermia (RT alone 68 % versus RT + HT 50 %, p = 0.04, and T-size (T4 75 % versus T2-3 36 %, p < 0.01). A Cox multivariate analysis showed the same factors to be the only significant prognostic parameters: hyperthermia (HR: 0.61 [0.38-0.98], and small tumor strata (HR: 0.46 [0.26-0.92]. Consequentially, more patients given RT + HT (36 %) survived without disease (DFS), than after RT alone (19 %), p = 0.021) CONCLUSION: A randomized multicenter trial investigating the addition of a weekly hyperthermia treatment to radiotherapy of patients with locally advanced breast cancer significantly enhanced the 5-year tumor control and yielded more patients surviving free from cancer. The results substantiate the potential clinical benefit of hyperthermic oncology.
引用
- Overgaard J, Ccm Hulshof M, Dahl O, et al. ESHO 1-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology. Radiother Oncol. 2024. PMID: 38670266. doi:10.1016/j.radonc.2024.110313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。